Biogen reports lupus data while Biogen stock trades at EUR 199.33

Published on 10/06/2026 at 09:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen stock costs EUR 199.33 on October 6, 2026 after EUR 197.76. Litifilimab reached 27.20 percent at Week 52 versus 19.00 percent at Week 24.

Schwarzweiß-Reportage: Sechs Wissenschaftler diskutieren Gehirnscans und Moleküldiagramme am Tisch — Biogen Inc. Neurologie-Forscher analysieren gemeinsam Gehirnscans und Moleküldaten im Konferenzraum ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. (ISIN US09062X1037) was trading at EUR 199.33 at Lang & Schwarz on October 6, 2026 at 9:21 a.m. CEST, while the latest AMETHYST data showed litifilimab reaching 27.20 percent clear or almost clear skin at Week 52, up from 19.00 percent at Week 24. GlobeNewswire reported on October 2, 2026 that Biogen presented the 52-week Phase 2 results from the ongoing Phase 2/3 study in cutaneous lupus erythematosus.

Litifilimab improves through Week 52

The study also recorded a 28.80 percent rate for a 70 percent or greater reduction in disease activity at Week 52, compared with 21.70 percent at Week 24. The Phase 2 portion evaluated 93 adults, giving the response data a defined clinical base rather than a broad pipeline claim.

The study's Phase 3 portion is expected to read out in the first half of 2027, according to GlobeNewswire. That timeline leaves the current value case tied to clinical durability and Biogen's established commercial portfolio while the later-stage evidence develops.

Revenue grows while profit falls

Biogen reported USD 2.74 billion of revenue and USD 97.5 million of net profit for the quarter ended June 30, 2026, according to Markets Insider on October 5, 2026. Revenue exceeded the USD 2.65 billion reported for the comparable quarter, while net profit fell from USD 634.8 million, a sharper earnings contrast than the top-line increase suggests.

Analyst positioning remains constructive but sits below the latest primary-market quote. Markets Insider reported on October 5, 2026 that Piper Sandler reiterated a Buy rating and set a USD 245.00 target, which lies 9.58 percent above the Nasdaq last price of USD 223.59 on October 5, 2026.

Biogen stock stays below its yearly high

Biogen's Nasdaq listing was last at USD 223.59 on October 5, 2026 at 4:00 p.m. ET, with a market capitalization of USD 33.0 billion. The company also said it will report third-quarter 2026 financial results on October 28, 2026, before the market opens, according to Biogen.

At Lang & Schwarz, Biogen stock was trading at EUR 199.33 on October 6, 2026 at 9:21 a.m. CEST, plus 0.79 percent versus the prior close of EUR 197.76 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Biogen stock.